主要な幹細胞(ステムセル)技術企業分析(2014-2024)...市場調査レポートについてご紹介

【英文タイトル】Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary
1.1 Top Stem Cell Technology Companies: Overview of Findings
1.2 Report Contents
1.3 Study Methods – Research and Analysis
1.4 Scope and Format of Report
2. Leading US Stem Cell Technology Companies, 2014
2.1 Aastrom Biosciences
2.1.1 Stem Cell Technology Platform
2.1.2 Aastrom: Stem Cell Pipeline, 2014
2.1.2.1 Ixmyelocel-T: Patient-Specific Therapy Reduces Risk of Rejection
2.1.2.2 Orphan Designation to Accelerate Product Development
2.1.3 Sales and Recent Performance, 2012
2.1.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
2.1.5 Aastrom: Stem Cell Revenue Forecast, 2014-2024
2.2 Advanced Cell Technology (ACT)
2.2.1 Stem Cell Technology Platform
2.2.2 ACT: Stem Cell R&D Pipeline, 2014
2.2.2.1 Human Embryonic Stem Cells: Aiding Tissue Repair
2.2.3 Sales and Recent Performance, 2012
2.2.4 ACT: Stem Cell SWOT Analysis, 2014-2024
2.2.5 ACT: Stem Cell Revenue Forecast, 2014-2024
2.3 Bioheart
2.3.1 Bioheart: Stem Cell Pipeline, 2014
2.3.2 Sales and Recent Performance, 2012
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
2.3.4.1 Increased Activity Abroad Will Help Bioheart Attract Investment
2.4 BrainStorm Cell Therapeutics
2.4.1 Brainstorm Cell Therapeutics: Stem Cell Pipeline, 2014
2.4.2 Brainstorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.4.3 Brainstorm Cell Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.4.3.1 Government Grant Will Provide Much Needed Investment
2.5 California Stem Cell Inc.
2.5.1 California Stem Cell: Stem Cell Pipeline, 2014
2.5.2 California Stem Cell: Stem Cells SWOT Analysis, 2014-2024
2.6 International Stem Cell Corporation (ISCO)
2.6.1 ISCO: Stem Cell Pipeline, 2014
2.6.2 Sales and Recent Performance, 2012
2.6.3 ISCO: Stem Cells SWOT Analysis, 2014-2024
2.6.4 Cosmetic Subsidiary Expands Into Asian Market
2.7 NeoStem
2.7.1 NeoStem: Stem Cell Pipeline, 2014
2.7.1.1 AMR-001: Highly Efficacious Therapy for AMI
2.7.1.2 T-Cell Therapy: Using Autologous Immune Cells as Therapy
2.7.1.3 VSEL Technology: Promoting Cell Migration to Site of Damage
2.7.2 Sales and Recent Performance, 2012
2.7.3 NeoStem: Stem Cell SWOT Analysis, 2014-2024
2.7.4 NeoStem: Stem Cell Revenue Forecast, 2014-2024
2.8 Neuralstem
2.8.1 Stem Cell Technology Platform
2.8.2 Neuralstem: Stem Cell Pipeline, 2014
2.8.2.1 NSI-566: Potential Therapy in Multiple Neurological Disorders
2.8.2.2 NSI-189: Deriving Cells from the Hippocampal Region
2.8.3 Sales and Recent Performance, 2012
2.8.4 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
2.8.5 Neuralstem: Stem Cell Revenue Forecast, 2014-2024
2.9 Medistem
2.9.1 Medistem: Stem Cell Pipeline, 2014
2.9.2 Medistem: Stem Cell SWOT Analysis, 2014-2024
2.9.3 Medistem: Stem Cell Revenue Forecast, 2014-2024
2.9.3.1 Expansion of Clinical Indications Through Acquisition
2.10 Osiris Therapeutics
2.10.1 Osiris Therapeutics: Stem Cell Products
2.10.2 Osiris Therapeutics: Stem Cell Pipeline, 2014
2.10.3 Sales and Recent Performance, 2012
2.10.4 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.10.5 Osiris Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.11 Other US Companies Operating in the Stem Cells Technology Industry, 2014
3. Top European and Israeli Stem Cell Technology Companies, 2014
3.1 Apceth
3.1.1 Apceth: Stem Cell Pipeline, 2014
3.1.1.1 Alecmestencel-T: Options for Autologous and Allogeneic Therapy
3.1.1.2 Agenmestencel-T: Genetically-modified Therapy for Cancer
3.1.2 Apceth: Stem Cell SWOT Analysis, 2014-2024
3.1.3 Apceth: Stem Cell Revenue Forecast, 2014-2024
3.2 Cardio3 BioSciences
3.2.1 Cardio3 BioSciences: Stem Cell Pipeline, 2014
3.2.1.1 C-Cure®: Creating New Muscle Cells
3.2.2 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
3.2.3 Cardio3 BioSciences: Stem Cell Revenue Forecast, 2014-2024
3.3 Cell Cure Neurosciences
3.3.1 Cell Cure Neurosciences: Stem Cell Pipeline, 2014
3.3.2 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
3.4 TiGenix
3.4.1 Stem Cell Technology Platform
3.4.2 TiGenix: Stem Cell Products
3.4.2.1 ChondroCelect: One of Few Marketed Stem Cell Products
3.4.3 TiGenix: Stem Cell Pipeline, 2014
3.4.3.1 Cx601: Promoting Natural Close of Fissure
3.4.3.2 Cx611: Landmark Results of a Cell Therapy in Rheumatoid Arthritis
3.4.3.3 Cx621: Novel, Painless Route of Administration?
3.4.4 Sales and Recent Performance, 2012
3.4.5 TiGenix: Stem Cell SWOT Analysis, 2014-2024
3.4.6 TiGenix: Stem Cell Revenue Forecast, 2014-2024
3.5 Gamida Cell
3.5.1 Stem Cell Technology Platform
3.5.1.1 Copper Chelator-based Technology
3.5.1.2 Nicotinamide (NAM) Platform
3.5.2 Gamida Cell: Stem Cell Pipeline, 2014
3.5.2.1 StemEx: Huge Market Potential in Patient Numbers
3.5.2.2 NiCord: Transplanting Two Units of Umbilical Cord Blood
3.5.3 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
3.5.4 Gamida Cell: Stem Cell Revenue Forecast, 2014-2024
3.6 Pluristem Therapeutics
3.6.1 Stem Cell Technology Platform:
3.6.2 Pluristem Therapeutics: Stem Cell Pipeline, 2014
3.6.2.1 PLX-PAD: Clinical Hold Notification May Delay Approval
3.6.2.2 PLX-RAD: Accelerating Cell Engraftment in Bone Marrow Transplantation
3.6.3 US and Korea Licence Partnerships to Drive Revenue
3.6.4 Sales and Recent Performance, 2013
3.6.5 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
3.6.6 Pluristem Therapeutics: Stem Cell Revenue Forecast, 2014-2024
3.7 ReNeuron
3.7.1 ReNeuron: Stem Cell Technology Platform
3.7.2 ReNeuron: Stem Cell Pipeline, 2014
3.7.2.1 ReN001: Groundbreaking Therapy in Development
3.7.2.2 ReN009: Avoiding Possible Limb Amputation
3.7.2.3 ReN003: Grant and Partnership with Leading US University Will Drive Development
3.7.3 Sales and Recent Performance, 2013
3.7.4 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
3.7.5 ReNeuron: Stem Cell Revenue Forecast, 2014-2024
3.8 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
4. Top Asia-Pacific Stem Cell Technology Companies, 2014
4.1 Anterogen
4.1.1 Anterogen: Stem Cell Products
4.1.1.1 Cupistem®: World’s First MSC Product From Adipose Tissue
4.1.1.2 Queencell®:
4.1.2 Anterogen: Stem Cell Pipeline, 2014
4.1.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
4.2 MEDIPOST
4.2.1 Stem Cell Technology Platform
4.2.2 MEDIPOST: Stem Cell Pipeline, 2014
4.2.2.1 Cartistem: A Top 25 Science Technology
4.2.2.2 Neurostem: Restorative Therapy for Neurological Disease
4.2.2.3 Pneumostem: Treatment for Paediatric Population
4.2.2.4 Promostem: Encouraging Engraftment of Cells Following Transplantation
4.2.3 Sales and Recent Performance, 2014
4.2.4 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
4.2.5 MEDIPOST: Stem Cell Revenue Forecast, 2014-2024
4.2.5.1 Collaboration with an Indian Company Expands Reach in Asia
4.3 Mesoblast
4.3.1 Stem Cell Technology Platform
4.3.2 Mesoblast: Stem Cell Pipeline, 2014
4.3.2.1 Immunology and Inflammatory Diseases
4.3.2.2 Spinal Disease
4.3.2.3 Cardiac and Vascular Disease
4.3.2.4 Oncology
4.3.2.5 Other Indications
4.3.3 Sales and Recent Performance, 2012
4.3.4 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
4.3.5 Mesoblast: Stem Cell Revenue Forecast, 2014-2024
4.4 Pharmicell
4.4.1 Pharmicell: Stem Cell Products
4.4.1.1 Hearticellgram-AMI: World First Cell Therapy for Acute Myocardial Infarction
4.4.2 Pharmicell: Stem Cell Pipeline, 2014
4.4.3 Sales and Recent Performance, 2012
4.4.4 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
4.4.5 Pharmicell: Stem Cell Revenue Forecast, 2014-2024
4.5 Stempeutics Research
4.5.1 Stem Cell Technology Platform
4.5.2 Stempeutics Research: Stem Cell Pipeline, 2014
4.5.2.1 Stempeucel®: Launch in Fast-Growing Asian Markets
4.5.2.2 Stempeucare™: Cosmetic Growth Factor Treatment
4.5.3 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
4.5.4 Stempeutics Research: Stem Cell Revenue Forecast, 2014-2024
4.5.4.1 Cipla Alliance to Drive Revenue as Wider Population Targeted
5. The World Stem Cell Technology Market, 2014-2024
5.1 The World Stem Cell Technology Market, 2012
5.2 The World Stem Cell Technology Market: Revenue Forecast to 2024
5.2.1 What Will Drive The World Stem Cell Technology Market Between 2014 and 2024?
5.2.2 What Factors are Likely to Restrain the World Stem Cell Technology Market Between 2014 and 2024?
5.3 The Stem Cell Technology Market: Revenue Forecast by Therapeutic Application, 2014-2024
5.3.1 How Will Market Shares of Leading Stem Cell Therapeutic Applications Change from 2014-2024?
6. Stem Cell Technologies: Industry Trends, 2014-2024
6.1 Strengths and Weaknesses of The Stem Cell Technologies Market
6.2 Strengths
6.2.1 Stem Cells Are Finally Proving Their Worth
6.3 Weaknesses
6.3.1 Many Difficulties Still to Overcome
6.4 Opportunities and Threats in the Stem Cell Technologies Market
6.4.1 Stem Cells Have Unprecedented Clinical Potential
6.4.2 Regulatory and Commercial Instability Threatens the Field
6.5 STEP Analysis of the Stem Cell Technologies Market, 2014-2024
6.5.1 Social Concerns: A Controversial Technology
6.5.2 Technological Developments: Stem Cell Science Still on the March
6.5.3 Economic Factors: Funding Gaps a Concern
6.5.4 Political Issues: State Attitudes Vital to Research Environment
7. Opinions from Research Interviews
7.1 Dr Robin Smith: Chairman and CEO, NeoStem
7.1.1 The Potential of Stem Cell Therapy
7.1.2 Competition in the Stem Cell Arena
7.1.3 NeoStem’s Products and Technology
7.1.4 Concerns over Stem Cell Therapy
7.1.5 Future Directions for NeoStem and Stem Cell Therapy
7.2 Dr Yael Margolin, President and CEO, Gamida Cell
7.2.1 Stem Cell Therapy and Their Therapeutic Promise
7.2.2 Gamida Cell’s NiCord Product and Umbilical Cord Blood
7.2.3 Partnership with a Leading Pharmaceutical Company
7.2.4 Barriers to Stem Cell Therapy Uptake
8. Conclusions
8.1 The US Leads the Field for Stem Cell Research
8.2 Market Remains Under-Capitalised, in Need of Financing
8.3 Many Barriers Still to Overcome for Companies
8.4 New Entrants to the Market Will Increase Competition


【レポート販売概要】

■ タイトル:主要な幹細胞(ステムセル)技術企業分析(2014-2024)
■ 英文:Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024
■ 発行日:2014年3月
■ 調査会社:visiongain
■ 商品コード:Visiongain-4052643
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。